Injectable Steroids

Stano 100 mg Vedi Pharma

Vedi Pharma

45,00

In Stock (100 available)

Stano 100 mg Vedi Pharma (100 mg) — Stanozolol — 17α-alkylated DHT-derivative that lowers SHBG and drives dry, hard tissue accrual. Zero aromatisation, zero water retention; the textbook cutting and pre-contest hardening compound.

100 in stock

This product is for laboratory research use only. Not for human consumption.

5+ −10%
10+ −15% Best price
Third-Party Lab Report HPLC verified
CoA available on request — email support@vitalquests.org with the batch code from your vial.
HPLC TestedBatch report available
No Labels on BoxPlain brown parcel
Pay the CourierCash on delivery only
Ships TodayOrder before 14:00
€85+ = free shipping
EU warehouse — no customs, no delays
Tracked via DHL / DPD / InPost

Description

Stano 100 mg Vedi Pharma — stanozolol from Vedi Pharma at 100 mg. DHT derivative that cannot aromatise, uniquely reduces SHBG by up to 50% (freeing other steroids for greater effect). Injectable aqueous suspension or oil; either way cosmetic hardening shows within 1–2 weeks.

Key Benefits

  • 17α-alkylated DHT-derivative — zero aromatisation, no water retention
  • Significant SHBG reduction — frees up more bound testosterone on cycle
  • Dramatic strength and hardness gains without scale-weight bloat
  • Available oral OR aqueous injectable — same molecule, different kinetics
  • Cutting and pre-contest staple when dry, vascular look is the goal
  • Each unit dosed at 100 mg — see Recommended Dosage below for protocol-specific intake

Recommended Dosage

Research dosing: oral 25–50 mg/day for 6–8 weeks, or injectable 50 mg every other day. Women 5–10 mg/day oral, short cycles only (4 weeks) — virilisation risk rises sharply beyond that. Above 50 mg/day SHBG crashes hard and joint dryness becomes limiting.

How It Works

17α-alkylated DHT-derivative. Does not aromatise. Distinctive mechanism: significant SHBG reduction that frees more co-administered testosterone to bind the AR. Minimal progestagenic activity. Androgenic effects at typical dose are low, but hair-follicle impact in genetically predisposed users is measurable.

Pharmacokinetics

Oral half-life ~9 hours; aqueous-suspension injectable ~24 hours. The injectable is the same molecule as the tablet — the suspension simply bypasses first-pass liver metabolism. Hepatotoxicity similar between routes since the 17α-alkyl group is preserved in both. ALT/AST at week 4.

Potential Side Effects

Joint pain from reduced synovial fluid is the signature complaint — fish oil 4 g/day helps. Lipid panel takes a big hit (HDL drops 30–50%). Androgenic side-effects dose-dependent. Liver markers rise; mandatory TUDCA support.

Cycle & Stacking Guide

Cutting and pre-contest hardening, 6–8 weeks. Standard stack: test base + stanozolol + trenbolone or masteron. Not a mass-builder — use methandienone or oxymetholone for that role. Avoid heavy pressing during cycle if joints are pre-compromised.

Manufacturer Notes

Vedi Pharma ships injectables in tamper-evident 10 ml vials with GMP-compliant batch numbering.

Storage & Handling

Store in the original blister or bottle at 15–25 °C, away from direct sunlight, heat, and humidity. Oral preparations lose potency faster if exposed to moisture; keep the desiccant (if included) with the tablets. Keep out of reach of children. For research and educational purposes only.

Reviews

There are no reviews yet.

Be the first to review “Stano 100 mg Vedi Pharma”

Your email address will not be published. Required fields are marked *